Abstracts

Search by keyword or author name.

Showing 851 abstracts.

Psychiatric disorder symptoms are associated with longitudinal changes in antiretroviral (ARV) non-adherence in perinatally HIV infected youth in the US: Results from IMPAACT P1055 New.

Study

P1055
Population Pharmacokinetics of Twice Daily Zidovudine (ZDV) in HIV-Infected Children: A Pooled Analysis from 6 international studies and an assessment of ZDV exposure following WHO weight band recommendations.
Changes in Tenofovir Population Pharmacokinetics during Pregnancy.

Study

P1026S
Clonal expansion, artificial censoring, and inverse probability weighting to compare the effects of multiple treatment management strategies after HAART failure among perinatally HIV-infected children and adolescents.
Influence of Age and Serum Creatinine on Population Pharmacokinetics of Emtricitabine in HIV-1 Infected Children.

Study

P1021
Safety and Efficacy of Dolutegravir (DTG; GSK1349572) in Treatment-Experienced HIV-1 Infected Adolescents: 24-Week Results from IMPAACT P1093.

Study

P1093
HIV-1 gp120 vaccination elicits a robust and durable anti-V1V2 IgG response and yet no HIV Env-specific IgA response in HIV-exposed infants.
Dose-finding Pharmacokinetics (PK) and 24- and 48-Week Safety and Efficacy of Raltegravir (RAL) Granules for Suspension (GFS) Formulation in Human Immunodeficiency Virus type-1 (HIV)-Infected Infants Starting Treatment at 4 Wk – 6 Mo of Age.

Study

P1066
Pharmacokinetics of Darunavir Once or Twice Daily During Pregnancy and Postpartum.

Study

P1026S
Use of Dried Blood Spot Samples and In-house Assays for Assessment of Drug Resistance in HIV-Infected Children in Resource-Limited Settings.

Study

P1060